A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
Links shared publicly online about this topic.
- 1,028total visits
A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
View full resource at clinicaltrials.gov
Tags: Cancer, Leukemia, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Rituxan
Most Recently Shared on July 12, 2010 at 12:04 pm By:
Relapsed or refractory fNHL? CAT-8015, possible next gen Rituxan, antibody targeting CD-22 in trial recruiting now. http://bit.ly/axXUqq
Advertisement
